Passing the Sniff Test: CHOP Researchers Identify SARS-CoV-2 Breath Biomarkers in Children

CHOP researchers have identified six biomarkers in the breath of children with COVID-19, laying the groundwork for a potential breathalyzer test.

Case Study: Treating Complex Pancreatitis in Youth

Read a case study about a patient treated by physicians from the Pancreatic Disorders Program.

Study Shows Benefit of Blinatumomab for High-Risk Relapsed B-ALL

A new study involving CHOP researchers show blinatumomab is less toxic and as good or better than chemotherapy for high-risk relapsed B-ALL.

Unexpected Consequence of the Pandemic: MIS-C-Related Cardiac Issues

In May 2020, the U.S. Centers for Disease Control and Prevention (CDC) defined multi-system inflammatory syndrome in children (MIS-C), which was the diagnosis in this case.

CHOP Researchers Find Effective Combination of Therapies for Managing Mitochondrial Disease

Study is first to demonstrate how one specific combinational therapy may provide measurable benefits to patients with mitochondrial respiratory chain disorders, which currently lack FDA-approved therapies.

Experts at Children’s Hospital of Philadelphia Describe Types of Rashes Associated with MIS-C

CHOP researchers describe different types of rashes they have seen in patients diagnosed with the COVID-19-related inflammatory syndrome.

CHOP Researchers Find NTRK Fusions More Common than Expected in Pediatric Tumors

CHOP researchers have found that NTRK fusions are more common than expected in pediatric tumors, which could lead to better screening and treatment.

CHOP Researchers Characterize Shared Pathways in Epilepsy and Autism

In a new study, CHOP researchers integrate data regarding how the conditions present clinically with data on protein-protein interactions.

CHOP and Penn Researchers Identify Nanoparticles that Could Be Used in Therapeutic mRNA Delivery before Birth

In a proof-of-concept study, CHOP and Penn researchers have identified ionizable lipid nanoparticles that could be used to deliver mRNA as part of fetal therapy.

FDA Approves Drug for Rare Form of Pediatric Cancer

The FDA has approved a treatment that targets ALK mutations in relapsed, refractory ALK-positive anaplastic large cell lymphoma.